Blood-based test can predict risk of developing symptoms of Alzheimer's up to a decade early

medicalxpress - A blood test for the biomarker phosphorylated tau 217 (p-tau217) recently received federal clearance, but questions have emerged about the extent to which such tests can accurately predict whether a cognitively healthy individual will develop cognitive im…

AI Summary: Researchers validated a blood‑based test that flags individuals at elevated risk of developing Alzheimer’s symptoms up to a decade earlier, showing strong predictive accuracy across cohorts. The finding could enable earlier monitoring and trial enrollment, but raises questions about screening protocols, follow‑up care and the psychological burden of long‑lead risk information.

#healthcare #publichealth #biotech #behavioralhealth #clinicaltrials #neuroscience #alzheimersdisease #diagnostics

Blood biomarkers forecast Alzheimer's risk years ahead (4)
Genetics and clearance mechanisms shaping Alzheimer's onset (3)
Sleep, frailty and resilience as non-blood early signals (3)

Blood biomarkers forecast Alzheimer's risk years ahead

Alzheimer's blood markers may reveal who benefits most from MIND diet

5 wks / medicalxpress

Study links sleeping long hours with higher levels of an Alzheimer's-related protein

6 wks / medicalxpress

Study shows blood test can help identify people at high risk for Alzheimer's disease

6 wks / abcnews

Blood-based test can predict risk of developing symptoms of Alzheimer's up to a decade early

6 wks / medicalxpress

Genetics and clearance mechanisms shaping Alzheimer's onset

Prion Diseases May Begin When Proteins Misfold, Triggering Rapid Brain Damage

5 wks / discovermagazine

Three genetic modifiers may alter inherited Alzheimer's onset and progression

5 wks / medicalxpress

Scientists discover hidden gateways that allow the brain to clear waste

5 wks / medicalxpress

Sleep, frailty and resilience as non-blood early signals

Exceptional memory in 80s defies simple Alzheimer's genetic risk explanation

5 wks / medicalxpress

AI and sleep analysis could facilitate early diagnosis of Alzheimer's

5 wks / medicalxpress

Frailty could be key to early dementia diagnosis

5 wks / medicalxpress

CVS Caremark, FTC settle insulin pricing case for $13B

Ella Jeffries / beckershospitalreview - The Federal Trade Commission reached a settlement with CVS Caremark that requires the pharmacy benefit manager to change its business practices as part of the agency’s antitrust case alleging the PBM inflated insulin list prices through rebate practices. …

AI Summary: CVS Caremark agreed to a $13 billion settlement with the Federal Trade Commission to resolve allegations tied to its handling of insulin pricing and related business practices. The deal includes a large cash payment and operational changes designed to address the FTC’s concerns, and now awaits court approval and implementation details.

#healthcare #pharmaceuticals #drugpricing #publichealth #governmentpolicy #healthcarefinance #pricetransparency #diabetes

Henry Ford Health sues CVS, alleges 340B pricing scheme

5 wks / beckershospitalreview / Ella Jeffries

CVS Caremark, FTC settle insulin pricing case for $13B

6 wks / beckershospitalreview / Ella Jeffries

FTC, CVS unveil settlement in ongoing insulin pricing case

6 wks / fiercehealthcare

CVS Caremark reaches settlement with FTC over insulin suit

6 wks / healthcaredive / Rebecca Pifer Parduhn

StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Clinical Trials, Eli Lilly, Pfizer, Long COVID and look for the RSS link.

StackHealth Time Machine

More StackHealth